Eric P Krenning

List of Publications by Year
in descending order

309 papers	25,238 citations	84 h-index	147 g-index
		5782	9605
318 all docs	318 docs citations	318 times ranked	16513 citing authors

#	Article	IF	Citations
1	Towards prevention of ischemia-reperfusion kidney injury: Pre-clinical evaluation of 6-chromanol derivatives and the lead compound SUL-138âœ°. European Journal of Pharmaceutical Sciences, 2022, 168, 106033.	1.9	4
2	Endothelial function after the exposition of magnesium degradation products. Materials Science and Engineering C, 2022, 134, 112693.	3.8	3
3	Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK2R Cancer Theranostic Agents: A Preclinical Study. Pharmaceutics, 2022, 14, 666.	2.0	3
4	Thoracic bilateral sympathectomy attenuates oxidative stress and prevents ventricular remodelling in experimental pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 2022, 61, 1337-1345.	0.6	1
5	The Endothelium as a Target for Anti-Atherogenic Therapy: A Focus on the Epigenetic Enzymes EZH2 and SIRT1. Journal of Personalized Medicine, 2021, 11, 103.	1.1	16
6	Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷Lu-DOTATATE. Journal of Nuclear Medicine, 2021, 62, 1712-1718.	2.8	12
7	Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. Cell Stem Cell, 2021, 28, 653-670.e11.	5.2	31
8	Calciprotein Particles. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1607-1624.	1.1	40
9	SUL-151 Decreases Airway Neutrophilia as a Prophylactic and Therapeutic Treatment in Mice after Cigarette Smoke Exposure. International Journal of Molecular Sciences, 2021, 22, 4991.	1.8	7
10	Autologous Lipofilling Improves Clinical Outcome in Patients With Symptomatic Dermal Scars Through Induction of a Pro-Regenerative Immune Response. Aesthetic Surgery Journal, 2021, , .	0.9	3
11	Torpor enhances synaptic strength and restores memory performance in a mouse model of Alzheimerâ€™s disease. Scientific Reports, 2021, 11, 15486.	1.6	5
12	The Effects of 6-Chromanol SUL-138 during Hypothermic Machine Perfusion on Porcine Deceased Donor Kidneys. Transplantology, 2021, 2, 304-314.	0.3	1
13	Reciprocal regulation of endothelialâ€“mesenchymal transition by MAPK7 and EZH2 in intimal hyperplasia and coronary artery disease. Scientific Reports, 2021, 11, 17764.	1.6	4
14	177Lu-Dotatate plus long-acting octreotide versus highâ€‘dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 1752-1763.	5.1	195
15	miRetrieveâ€”an R package and web application for miRNA text mining. NAR Genomics and Bioinformatics, 2021, 3, lqab117.	1.5	2
16	PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 895-906.	3.3	73
17	Glomerular Endothelial Cells as Instigators of Glomerular Sclerotic Diseases. Frontiers in Pharmacology, 2020, 11, 573557.	1.6	50
18	Optimizing the Profile of [99mTc]Tcâ€“NT(7â€“13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors. International Journal of Molecular Sciences, 2020, 21, 7926.	1.8	7

#	Article	IF	Citations
19	Nitric Oxide-cGMP Signaling in Hypertension. Hypertension, 2020, 76, 1055-1068.	1.3	39
20	[99mTc]Tc-DB1 Mimics with Different-Length PEG Spacers: Preclinical Comparison in GRPR-Positive Models. Molecules, 2020, 25, 3418.	1.7	8
21	One Step Closer to Clinical Translation: Enhanced Tumor Targeting of [99mTc]Tc-DB4 and [111In]In-SG4 in Mice Treated with Entresto. Pharmaceutics, 2020, 12, 1145.	2.0	9
22	microRNA Expression Profile in the Vitreous of Proliferative Diabetic Retinopathy Patients and Differences from Patients Treated with Anti-VEGF Therapy. Translational Vision Science and Technology, 2020, 9, 16.	1.1	19
23	Human Milk Oligosaccharides Mediate the Crosstalk Between Intestinal Epithelial Caco-2 Cells and Lactobacillus Plantarum WCFS1in an In Vitro Model with Intestinal Peristaltic Shear Force. Journal of Nutrition, 2020, 150, 2077-2088.	1.3	19
24	Activation of Retinal Angiogenesis in Hyperglycemic pdx1 â^'/â^' Zebrafish Mutants. Diabetes, 2020, 69, 1020-1031.	0.3	30
25	Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands. Pharmaceutics, 2020, 12, 528.	2.0	8
26	MicroRNAs linking oxidative stress and diabetes. , 2020, , 97-106.		0
27	Non-coding RNA in endothelial-to-mesenchymal transition. Cardiovascular Research, 2019, 115, 1716-1731.	1.8	56
28	Klotho Deficiency Induces Arteriolar Hyalinosis in a Trade-Off with Vascular Calcification. American Journal of Pathology, 2019, 189, 2503-2515.	1.9	6
29	The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the Î±1-adrenoceptor. Scientific Reports, 2019, 9, 13.	1.6	28
30	Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair. Molecules, 2019, 24, 1015.	1.7	11
31	Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses. Pharmaceuticals, 2019, 12, 42.	1.7	8
32	Comparative evaluation of the new GRPRâ€antagonist ¹¹¹Inâ€SB9 and ¹¹¹Inâ€AMBA in prostate cancer models: Implications of in vivo stability. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 646-655.	0.5	10
33	P1940Reciprocal regulation of Endothelial-Mesenchymal Transition by MAPK7 and EZH2 activity in Intimal Hyperplasia and Coronary Artery Disease. European Heart Journal, 2019, 40, .	1.0	0
34	MicroRNAâ€374b induces endothelialâ€toâ€mesenchymal transition and early lesion formation through the inhibition of MAPK7 signaling. Journal of Pathology, 2019, 247, 456-470.	2.1	22
35	Endothelial to Mesenchymal Transition inÂCardiovascular Disease. Journal of the American College of Cardiology, 2019, 73, 190-209.	1.2	357
36	PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1155-1169.	3.3	101

#	Article	IF	Citations
37	Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin. Bioconjugate Chemistry, 2018, 29, 1774-1784.	1.8	27
38	Endothelialâ€“mesenchymal transition in atherosclerosis. Cardiovascular Research, 2018, 114, 565-577.	1.8	239
39	The 6-hydroxychromanol derivative SUL-109 ameliorates renal injury after deep hypothermia and rewarming in rats. Nephrology Dialysis Transplantation, 2018, 33, 2128-2138.	0.4	15
40	Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2018, 59, 452-458.	2.8	88
41	Human adipose tissue-derived stromal cells act as functional pericytes in mice and suppress high-glucose-induced proinflammatory activation of bovine retinal endothelial cells. Diabetologia, 2018, 61, 2371-2385.	2.9	34
42	Obituary of Professor T.J. Visser. European Thyroid Journal, 2018, 7, 163-164.	1.2	0
43	Epigenetic Regulation of Endothelial-to-Mesenchymal Transition in Chronic Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1986-1996.	1.1	63
44	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clinical Cancer Research, 2017, 23, 4617-4624.	3.2	399
45	Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Endocrine-Related Cancer, 2017, 24, 243-251.	1.6	45
46	The microRNA-7-mediated reduction in EPAC-1 contributes to vascular endothelial permeability and eNOS uncoupling in murine experimental retinopathy. Acta Diabetologica, 2017, 54, 581-591.	1.2	13
47	The 6-chromanol derivate SUL-109 enables prolonged hypothermic storage of adipose tissue-derived stem cells. Biomaterials, 2017, 119, 43-52.	5.7	31
48	Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. Journal of Nuclear Medicine, 2017, 58, 3S-9S.	2.8	66
49	Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. Journal of Nuclear Medicine, 2017, 58, 75-80.	2.8	129
50	FGF-2 inhibits Endothelial-Mesenchymal Transition through microRNA-20a-mediated repression of canonical TGF-Î² Signaling. Journal of Cell Science, 2016, 129, 569-79.	1.2	77
51	Micromanaging cardiac regeneration: Targeted delivery of microRNAs for cardiac repair and regeneration. World Journal of Cardiology, 2016, 8, 163.	0.5	26
52	Endothelial Plasticity: Shifting Phenotypes through Force Feedback. Stem Cells International, 2016, 2016, 1-15.	1.2	55
53	The novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease. Scientific Reports, 2016, 6, 26928.	1.6	12
54	Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer. Seminars in Nuclear Medicine, 2016, 46, 225-238.	2.5	97

#	Article	IF	Citations
55	99mTc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice. Nuclear Medicine and Biology, 2016, 43, 347-354.	0.3	15
56	Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1802-1811.	3.3	129
57	761 Circulating Neuroendocrine Gene Transcripts Accurately Identify GEP-NETs, Are Decreased by Surgery and Predict Tumor Progression and Recurrence. Gastroenterology, 2016, 150, S154.	0.6	0
58	Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11â€"first estimates for clinical translation. EJNMMI Research, 2016, 6, 15.	1.1	23
59	Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 964-973.	3.3	90
60	Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon. Cancer Biotherapy and Radiopharmaceuticals, 2016, 31, 20-28.	0.7	24
61	Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 453-463.	3.3	125
62	Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics of North America, 2016, 30, 179-191.	0.9	106
63	The decrease in histone methyltransferase EZH2 in response to fluid shear stress alters endothelial gene expression and promotes quiescence. Angiogenesis, 2016, 19, 9-24.	3.7	62
64	Enhancer of zeste homolog-2 (EZH2) methyltransferase regulates transgelin/smooth muscle-22Î± expression in endothelial cells in response to interleukin-1Î² and transforming growth factor-Î²2. Cellular Signalling, 2015, 27, 1589-1596.	1.7	56
65	In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands. Nuclear Medicine and Biology, 2015, 42, 824-832.	0.3	15
66	Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 5-19.	3.3	357
67	MicroRNAs in Tissue Engineering and Regenerative Medicine. , 2015, , 1159-1200.		1
68	Endothelial-to-mesenchymal transition contributes to fibro-proliferative vascular disease and is modulated by fluid shear stress. Cardiovascular Research, 2015, 108, 377-386.	1.8	189
69	Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate. Journal of Nuclear Medicine, 2015, 56, 1647-1653.	2.8	97
70	[¹¹¹In-DTPA]octreotide Tumor Uptake in GEPNET Liver Metastases After Intra-Arterial Administration: An Overview of Preclinical and Clinical Observations and Implications for Tumor Radiation Dose After Peptide Radionuclide Therapy. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 179-187.	0.7	23
71	Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptorâ€"Expressing Neuroendocrine Tumors. Pancreas, 2014, 43, 518-525.	0.5	120
72	Neuroendocrine tumours: the role of imaging for diagnosis and therapy. Nature Reviews Endocrinology, 2014, 10, 102-114.	4.3	120

#	Article	IF	Citations
73	In Vivo Enzyme Inhibition Improves the Targeting of [¹⁷⁷Lu]DOTA-GRP(13â€“27) in GRPR-Positive Tumors in Mice. Cancer Biotherapy and Radiopharmaceuticals, 2014, 29, 359-367.	0.7	9
74	â€œTo Serve and Protectâ€ Enzyme Inhibitors as Radiopeptide Escorts Promote Tumor Targeting. Journal of Nuclear Medicine, 2014, 55, 121-127.	2.8	101
75	Interaction between Epac1 and miRNA-7 in airway smooth muscle cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387, 795-797.	1.4	12
76	[¹¹¹In-DOTA]LTT-SS28, a First Pansomatostatin Radioligand for in Vivo Targeting of Somatostatin Receptor-Positive Tumors. Journal of Medicinal Chemistry, 2014, 57, 6564-6571.	2.9	18
77	[DOTA]Somatostatin-14 analogs and their 111In-radioligands: Effects of decreasing ring-size on sst1â€“5 profile, stability and tumor targeting. European Journal of Medicinal Chemistry, 2014, 73, 30-37.	2.6	12
78	Combined implantation of CD34 + and CD14 + cells increases neovascularization through amplified paracrine signalling. Journal of Tissue Engineering and Regenerative Medicine, 2013, 7, 118-128.	1.3	8
79	Adipose stromal cells primed with hypoxia and inflammation enhance cardiomyocyte proliferation rate in vitro through STAT3 and Erk1/2. Journal of Translational Medicine, 2013, 11, 39.	1.8	57
80	The flow dependency of Tie2 expression in endotoxemia. Intensive Care Medicine, 2013, 39, 1262-1271.	3.9	39
81	Hypocalcaemia after treatment with [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1843-1852.	3.3	6
82	Tumor Diagnosis with New ¹¹¹In-Radioligands Based on Truncated Human Gastrin Releasing Peptide Sequences: Synthesis and Preclinical Comparison. Journal of Medicinal Chemistry, 2013, 56, 8579-8587.	2.9	13
83	IL-1Î² and TGFÎ²2 synergistically induce endothelial to mesenchymal transition in an NFÎºB-dependent manner. Immunobiology, 2013, 218, 443-454.	0.8	171
84	Gastrin Releasing Peptide Receptor-Directed Radioligands Based on a Bombesin Antagonist: Synthesis, ¹¹¹In-Labeling, and Preclinical Profile. Journal of Medicinal Chemistry, 2013, 56, 2374-2384.	2.9	28
85	The Effect of Donor Variation and Senescence on Endothelial Differentiation of Human Mesenchymal Stromal Cells. Tissue Engineering - Part A, 2013, 19, 2318-2329.	1.6	26
86	Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy. Neuroendocrinology, 2013, 97, 74-85.	1.2	58
87	mTOR Inhibitor RAD001 Promotes Metastasis in a Rat Model of Pancreatic Neuroendocrine Cancer. Cancer Research, 2013, 73, 12-18.	0.4	39
88	^{99m}Tc Radiotracers Based on Human GRP(18-27): Synthesis and Comparative Evaluation. Journal of Nuclear Medicine, 2013, 54, 1797-1803.	2.8	21
89	Comparison of Response Evaluation in Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors After Treatment with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate. Journal of Nuclear Medicine, 2013, 54, 1689-1696.	2.8	41
90	Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors: Differential Response of Bone Versus Soft-Tissue Lesions. Journal of Nuclear Medicine, 2012, 53, 1359-1366.	2.8	20

#	Article	IF	Citations
91	Reduction of Renal Uptake of Radiolabeled Octreotate by Amifostine Coadministration. Journal of Nuclear Medicine, 2012, 53, 749-753.	2.8	18
92	Cellular plasticity: the good, the bad, and the ugly? Microenvironmental influences on progenitor cell therapy. Canadian Journal of Physiology and Pharmacology, 2012, 90, 275-285.	0.7	10
93	A global downregulation of microRNAs occurs in human quiescent satellite cells during myogenesis. Differentiation, 2012, 84, 314-321.	1.0	42
94	Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2012, 26, 867-881.	1.0	58
95	[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study. EJNMMI Research, 2012, 2, 25.	1.1	24
96	Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 2011, 40, 173-185.	1.2	59
97	68Ga-labeled DOTA-Peptides and 68Ga-labeled Radiopharmaceuticals for Positron Emission Tomography: Current Status of Research, Clinical Applications, and Future Perspectives. Seminars in Nuclear Medicine, 2011, 41, 314-321.	2.5	183
98	Somatostatin analogs for the treatment of neuroendocrine tumors. Cancer and Metastasis Reviews, 2011, 30, 9-17.	2.7	45
99	Reduction of 68Ge activity containing liquid waste from 68Ga PET chemistry in nuclear medicine and radiopharmacy by solidification. Journal of Radioanalytical and Nuclear Chemistry, 2011, 288, 303-306.	0.7	2
100	Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 57-68.	3.3	79
101	Imaging of activated macrophages in experimental osteoarthritis using folate-targeted animal single-photon-emission computed tomography/computed tomography. Arthritis and Rheumatism, 2011, 63, 1898-1907.	6.7	57
102	Characteristics of SnO2-based 68Ge/68Ga generator and aspects of radiolabelling DOTA-peptides. Applied Radiation and Isotopes, 2011, 69, 308-315.	0.7	88
103	Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocrine-Related Cancer, 2011, 18, S27-S51.	1.6	104
104	The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0. Journal of Nuclear Medicine Technology, 2011, 39, 317-324.	0.4	74
105	The relation between 25-hydroxyvitamin D with peak bone mineral density and body composition in healthy young adults. Journal of Pediatric Endocrinology and Metabolism, 2011, 24, 355-60.	0.4	25
106	Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate. Journal of Nuclear Medicine, 2011, 52, 1361-1368.	2.8	161
107	Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1018-1031.	3.3	113
108	A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1386-1396.	3.3	67

#	Article	IF	Citations
109	Androgenâ€regulated gastrinâ€releasing peptide receptor expression in androgenâ€dependent human prostate tumor xenografts. International Journal of Cancer, 2010, 126, 2826-2834.	2.3	23
110	The origin of fibroblasts and mechanism of cardiac fibrosis. Journal of Cellular Physiology, 2010, 225, 631-637.	2.0	509
111	Optimization of the culturing conditions of human umbilical cord bloodâ€derived endothelial colonyâ€forming cells under xenoâ€free conditions applying a transcriptomic approach. Genes To Cells, 2010, 15, 671-687.	0.5	17
112	Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2010, 17, R53-R73.	1.6	409
113	Dynamic and Static Small-Animal SPECT in Rats for Monitoring Renal Function After ¹⁷⁷Lu-Labeled Tyr³-Octreotate Radionuclide Therapy. Journal of Nuclear Medicine, 2010, 51, 1962-1968.	2.8	30
114	NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors. Pancreas, 2010, 39, 784-798.	0.5	161
115	Salvage Therapy with ¹⁷⁷Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine, 2010, 51, 383-390.	2.8	112
116	Nephrotoxicity in Mice After Repeated Imaging Using ¹¹¹In-Labeled Peptides. Journal of Nuclear Medicine, 2010, 51, 973-977.	2.8	29
117	Endothelial progenitor cells give rise to pro-angiogenic smooth muscle-like progeny. Cardiovascular Research, 2010, 86, 506-515.	1.8	109
118	545 PEPTIDE RECEPTOR TARGETING IS SUPERIOR TO METABOLIC TARGETING FOR IN VIVO IMAGING OF HUMAN PROSTATE CANCER XENOGRAFTS. Journal of Urology, 2010, 183, .	0.2	0
119	Role of Somatostatins in Gastroenteropancreatic Neuroendocrine Tumor Development and Therapy. Gastroenterology, 2010, 139, 742-753.e1.	0.6	177
120	Peak bone mineral density, lean body mass and fractures. Bone, 2010, 46, 336-341.	1.4	140
121	Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2010, 40, 78-88.	2.5	140
122	Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy. Seminars in Nuclear Medicine, 2010, 40, 209-218.	2.5	95
123	Bone Mineral Density and Body Composition in Adolescents with Childhood-Onset Growth Hormone Deficiency. Hormone Research in Paediatrics, 2009, 71, 364-371.	0.8	26
124	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with ¹¹¹In-Pentetreotide. Neuroendocrinology, 2009, 90, 184-189.	1.2	162
125	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs. Neuroendocrinology, 2009, 90, 220-226.	1.2	232
126	Bone Mineral Density, Growth, and Thyroid Function in Long-Term Survivors of Pediatric Hodgkinâ€™s Lymphoma Treated with Chemotherapy Only. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1904-1909.	1.8	28

#	Article	IF	Citations
127	Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease. American Journal of Physiology - Renal Physiology, 2009, 296, F1314-F1322.	1.3	70
128	Pleiotropism of Adiponectin. Circulation Research, 2009, 104, 1029-1031.	2.0	17
129	CD34⁺ cells augment endothelial cell differentiation of CD14⁺ endothelial progenitor cells in vitro. Journal of Cellular and Molecular Medicine, 2009, 13, 2521-2533.	1.6	42
130	Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1138-1146.	3.3	151
131	Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1265-1272.	3.3	76
132	Effects of therapy with [177Lu-DOTA0,Tyr3]octreotate on endocrine function. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1758-1766.	3.3	38
133	Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1968-1976.	3.3	36
134	Endothelial progenitor cell-based neovascularization: implications for therapy. Trends in Molecular Medicine, 2009, 15, 180-189.	3.5	148
135	Peptide-receptor radionuclide therapy for endocrine tumors. Nature Reviews Endocrinology, 2009, 5, 382-393.	4.3	152
136	Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues. Accounts of Chemical Research, 2009, 42, 873-880.	7.6	168
137	Recurrent incarceration of the retroverted gravid uterus at term - two times transvaginal caesarean section: a case report. Journal of Medical Case Reports, 2009, 3, 103.	0.4	25
138	Vascular smooth muscle cells for use in vascular tissue engineering obtained by endothelial-to-mesenchymal transdifferentiation (EnMT) on collagen matrices. Biomaterials, 2008, 29, 3703-3711.	5.7	70
139	Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 743-748.	3.3	121
140	Hormonal crises following receptor radionuclide therapy with the radiolabeled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 749-755.	3.3	104
141	Heparin coating of poly(ethylene terephthalate) decreases hydrophobicity, monocyte/leukocyte interaction and tissue interaction. Colloids and Surfaces B: Biointerfaces, 2008, 67, 46-53.	2.5	15
142	Generating New Blood Flow: Integrating Developmental Biology and Tissue Engineering. Trends in Cardiovascular Medicine, 2008, 18, 312-323.	2.3	19
143	Gastroenteropancreatic neuroendocrine tumours. Lancet Oncology, The, 2008, 9, 61-72.	5.1	1,474
144	Pemetrexed Improves Tumor Selectivity of ¹¹¹In-DTPA-Folate in Mice with Folate Receptorâ€“Positive Ovarian Cancer. Journal of Nuclear Medicine, 2008, 49, 623-629.	2.8	52

#	Article	IF	Citations
145	Treatment With the Radiolabeled Somatostatin Analog [¹⁷⁷Lu-DOTA⁰,Tyr³]Octreotate: Toxicity, Efficacy, and Survival. Journal of Clinical Oncology, 2008, 26, 2124-2130.	0.8	1,307
146	SPECT Study of Folate Receptor-Positive Malignant and Normal Tissues in Mice Using a Novel ^{99m}Tc-Radiofolate. Journal of Nuclear Medicine, 2008, 49, 310-317.	2.8	73
147	Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide. Nuclear Medicine Communications, 2008, 29, 283-290.	0.5	19
148	Peptides for Radionuclide Therapy. , 2008, , 117-144.		4
149	Diagnostic imaging of dopamine receptors in pituitary adenomas. European Journal of Endocrinology, 2007, 156, S53-S56.	1.9	15
150	From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with In Vivo 99mTc-DMSA-SPECT and Molecular Imaging. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 40-49.	0.7	25
151	Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. Nuclear Medicine and Biology, 2007, 34, 633-641.	0.3	58
152	Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys. Nuclear Medicine and Biology, 2007, 34, 603-608.	0.3	22
153	Diagnostic Versus Therapeutic Doses of [177Lu-DOTA-Tyr3]-Octreotate: Uptake and Dosimetry in Somatostatin Receptor-Positive Tumors and Normal Organs. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 151-159.	0.7	14
154	Treatment of Patients Who Have Endocrine Gastroenteropancreatic Tumors with Radiolabeled Somatostatin Analogues. Hematology/Oncology Clinics of North America, 2007, 21, 561-573.	0.9	25
155	Five Stabilized111In-Labeled Neurotensin Analogs in Nude Mice Bearing HT29 Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 374-382.	0.7	4
156	Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta OncolÃ³gica, 2007, 46, 723-734.	0.8	200
157	Peptide receptor radionuclide therapy. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 111-129.	2.2	120
158	The kinetics of thyroid hormone transporters and their role in non-thyroidal illness and starvation. Best Practice and Research in Clinical Endocrinology and Metabolism, 2007, 21, 323-338.	2.2	10
159	Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 219-227.	3.3	45
160	Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 763-771.	3.3	43
161	Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1219-1227.	3.3	121
162	Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 1854-1860.	3.3	38

#	Article	IF	Citations
163	Efficient differentiation of CD14+ monocytic cells into endothelial cells on degradable biomaterials. Biomaterials, 2007, 28, 1470-1479.	5.7	41
164	Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. Journal of Nuclear Medicine, 2007, 48, 88-93.	2.8	36
165	Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors. Seminars in Nuclear Medicine, 2006, 36, 147-156.	2.5	283
166	Staging and treatment of differentiated thyroid carcinoma with radiolabeled somatostatin analogs. Trends in Endocrinology and Metabolism, 2006, 17, 19-25.	3.1	42
167	Quantification of [3H]docetaxel in feces and urine: development and validation of a combustion method. Anti-Cancer Drugs, 2006, 17, 63-67.	0.7	3
168	No difference between prednisolone and dexamethasone treatment in bone mineral density and growth in long term survivors of childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2006, 46, 88-93.	0.8	47
169	Somatostatin receptor imaging for neuroendocrine tumors. Pituitary, 2006, 9, 243-248.	1.6	69
170	Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 749-750.	3.3	1
171	[99mTc]Demotate 2 in the detection of sst2-positive tumours: a preclinical comparison with [111In]DOTA-tate. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 831-840.	3.3	26
172	Prognostic Implications of a Normal Stress Technetium-99mâ€“Tetrofosmin Myocardial Perfusion Study in Patients With a Healed Myocardial Infarct and/or Previous Coronary Revascularization. American Journal of Cardiology, 2006, 97, 1-6.	0.7	23
173	Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?. European Journal of Endocrinology, 2006, 155, 717-723.	1.9	20
174	Anticancer activity of targeted proapoptotic peptides. Journal of Nuclear Medicine, 2006, 47, 122-9.	2.8	19
175	Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. Journal of Nuclear Medicine, 2006, 47, 1599-606.	2.8	109
176	Inhibition of kidney uptake of radiolabeled somatostatin analogs: amino acids or gelofusine?. Journal of Nuclear Medicine, 2006, 47, 1730-1; author reply 1731.	2.8	7
177	Radiolabelling DOTA-peptides with 68Ga. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 478-485.	3.3	248
178	Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. European Journal of Nuclear Medicine and Molecular Imaging, 2005, 32, 1136-1143.	3.3	105
179	Peptide receptor radionuclide therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 595-616.	1.0	72
180	Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. Journal of Clinical Oncology, 2005, 23, 2754-2762.	0.8	602

#	Article	IF	Citations
181	Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 13S-7S.	2.8	92
182	Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 62S-6S.	2.8	103
183	Candidates for peptide receptor radiotherapy today and in the future. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 67S-75S.	2.8	57
184	Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 76S-82S.	2.8	11
185	Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 83S-91S.	2.8	117
186	Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 92S-8S.	2.8	60
187	Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 99S-106S.	2.8	107
188	Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 107S-14S.	2.8	14
189	Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides. Journal of Nuclear Medicine, 2005, 46 Suppl 1, 191S-8S.	2.8	7
190	Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide. Journal of Nuclear Medicine, 2005, 46, 2057-60.	2.8	12
191	Somatostatin Receptor Imaging. Growth Hormone, 2004, , 203-214.	0.2	1
192	Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrology Dialysis Transplantation, 2004, 19, 2275-2281.	0.4	50
193	Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177Lu-DOTA0,Tyr3]octreotate. Journal of Clinical Oncology, 2004, 22, 2724-2729.	0.8	191
194	Molecular Imaging and Treatment of Malignant Gliomas Following Adenoviral Transfer of the Herpes Simplex Virus-Thymidine Kinase Gene and the Somatostatin Receptor Subtype 2 Gene. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 111-120.	0.7	15
195	Peptide Receptor Radionuclide Therapy. Annals of the New York Academy of Sciences, 2004, 1014, 234-245.	1.8	80
196	Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+. Nuclear Medicine and Biology, 2004, 31, 821-824.	0.3	18
197	Long-term prognostic value of dobutamine stress echocardiography compared with myocardial perfusion scanning in patients unable to perform exercise tests. American Journal of Medicine, 2004, 117, 1-9.	0.6	45
198	Site-Specific Intracoronary Delivery of Octreotide in Humans: A Pharmacokinetic Study to Determine Dose-Efficacy in Restenosis Prevention. Journal of Cardiovascular Pharmacology, 2004, 43, 133-139.	0.8	1

#	Article	IF	Citations
199	Liver and Vertebral Uptake of Tc-99m Macroaggregated Albumin (MAA). Clinical Nuclear Medicine, 2004, 29, 793-794.	0.7	16
200	Somatostatin Receptor Targeted-Radio-Ablation of Tumors. Growth Hormone, 2004, , 233-249.	0.2	1
201	Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose. Journal of Nuclear Medicine, 2004, 45, 709-13.	2.8	25
202	Inhomogeneous localization of radioactivity in the human kidney after injection of [(111)In-DTPA]octreotide. Journal of Nuclear Medicine, 2004, 45, 1168-71.	2.8	49
203	A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. Journal of Nuclear Medicine, 2004, 45, 1260-9.	2.8	49
204	Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog. Journal of Nuclear Medicine, 2004, 45, 1716-20.	2.8	19
205	Octreoscan Radioreceptor Imaging. Endocrine, 2003, 20, 307-312.	2.2	54
206	Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 9-15.	3.3	266
207	99mTc-tetrofosmin or 99mTc-sestamibi for double-phase parathyroid scintigraphy?. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 193-196.	3.3	22
208	The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 312-315.	3.3	62
209	Radiolabelled peptides for tumour therapy: current status and future directions. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 463-469.	3.3	114
210	86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)â€"a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 510-518.	3.3	212
211	Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 917-920.	3.3	194
212	Preoperative comparison of different noninvasive strategies for predicting improvement in left ventricular function after coronary artery bypass grafting. American Journal of Cardiology, 2003, 92, 1-4.	0.7	31
213	Relation between QT dispersion and myocardial viability in ischemic cardiomyopathy. American Journal of Cardiology, 2003, 92, 712-715.	0.7	11
214	Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model. International Journal of Cancer, 2003, 104, 376-379.	2.3	34
215	Tyr3-Octreotide and Tyr3-Octreotate Radiolabeled with 177Lu or 90Y: Peptide Receptor Radionuclide Therapy Results In Vitro. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 761-768.	0.7	22
216	In Vivo and In Vitro Detection of Dopamine D2 Receptors in Uveal Melanomas. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 895-902.	0.7	9

#	Article	IF	Citations
217	Peptides and Monoclonal Antibodies in Oncology: An Introduction. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 591-592.	0.7	1
218	Diffuse Lung and Stomach Uptake of Tc-99m Oxidronate (HDP). Clinical Nuclear Medicine, 2003, 28, 845-846.	0.7	2
219	Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide. Journal of Nuclear Medicine, 2003, 44, 98-104.	2.8	42
220	Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs. Journal of Nuclear Medicine, 2003, 44, 1315-21.	2.8	51
221	Long-Term Effects of Growth Hormone Therapy on Bone Mineral Density, Body Composition, and Serum Lipid Levels in Growth Hormone Deficient Children: A 6-Year Follow-Up Study. Hormone Research in Paediatrics, 2002, 58, 207-214.	0.8	50
222	Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience. Seminars in Nuclear Medicine, 2002, 32, 110-122.	2.5	364
223	Somatostatin receptor imaging. Seminars in Nuclear Medicine, 2002, 32, 84-91.	2.5	212
224	Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Seminars in Nuclear Medicine, 2002, 32, 133-140.	2.5	307
225	Altered bone mineral density and body composition, and increased fracture risk in childhood acute lymphoblastic leukemia. Journal of Pediatrics, 2002, 141, 204-210.	0.9	196
226	Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 768-774.	3.3	49
227	Efficacy of percutaneous intramyocardial injections using a nonfluoroscopic 3-D mapping based catheter system. Cardiovascular Drugs and Therapy, 2002, 16, 527-533.	1.3	17
228	Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. Journal of Nuclear Medicine, 2002, 43, 1650-6.	2.8	63
229	The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy. Journal of Nuclear Medicine, 2002, 43, 1681-7.	2.8	6
230	Perfusion and Contractile Reserve in Chronic Dysfunctional Myocardium: Relation to Functional Outcome After Surgical Revascularization. Circulation, 2002, 106, .	1.6	13
231	Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1421-1429.	2.2	193
232	[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1319-1325.	2.2	431
233	[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. International Journal of Cancer, 2001, 92, 628-633.	2.3	176
234	Thyroid Hormone Transport by the Heterodimeric Human System L Amino Acid Transporter. Endocrinology, 2001, 142, 4339-4348.	1.4	158

#	Article	IF	Citations
235	[¹²³I]Metaiodobenzylguanidine and[¹¹¹In]Octreotide Uptake in Benign and Malignant Pheochromocytomas¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 685-693.	1.8	233
236	Plasma Membrane Transport of Thyroid Hormones and Its Role in Thyroid Hormone Metabolism and Bioavailability. Endocrine Reviews, 2001, 22, 451-476.	8.9	340
237	[177Lu-DOTA0,Tyr3]octreotate for somatostatin receptor-targeted radionuclide therapy. , 2001, 92, 628.		4
238	Safety, Hemodynamic Profile, and Feasibility of Dobutamine Stress Technetium Myocardial Perfusion Single-Photon Emission CT Imaging for Evaluation of Coronary Artery Disease in the Elderly. Chest, 2000, 117, 649-656.	0.4	33
239	Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukemia in childhood. Medical and Pediatric Oncology, 2000, 35, 415-420.	1.0	113
240	Accuracy of exercise stress technetium 99m sestamibi SPECT imaging in the evaluation of the extent and location of coronary artery disease in patients with an earlier myocardial infarction. Journal of Nuclear Cardiology, 2000, 7, 432-438.	1.4	30
241	Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 1312-1317.	2.2	72
242	Therapeutic use of radiolabelled peptides. Annals of Oncology, 2000, 11, 267-272.	0.6	6
243	Accuracy of dobutamine tetrofosmin myocardial perfusion imaging for the noninvasive diagnosis of transplant coronary artery stenosis. Journal of Heart and Lung Transplantation, 2000, 19, 360-366.	0.3	39
244	Scintigraphy of Pancreatic Neuroendocrine Tumors and Carcinoids. Growth Hormone, 2000, , 235-249.	0.2	1
245	Tc-99m Sestamibi Before and During Treatment in a Patient With Sarcoidosis and Persistent Hyperparathyroidism. Clinical Nuclear Medicine, 2000, 25, 351-353.	0.7	3
246	Dobutamine stress thallium-201 single-photon emission tomography versus echocardiography for evaluation of the extent and location of coronary artery disease late after myocardial infarction. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 467-473.	3.3	4
247	Tumour uptake of the radiolabelled somatostatin analogue [DOTA 0 ,TYR 3]octreotide is dependent on the peptide amount. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 693-698.	3.3	81
248	Dobutamine stress echocardiography and technetium-99m-tetrofosmin/fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction. American Journal of Cardiology, 1999, 84, 130-134.	0.7	22
249	Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. , 1999, 81, 658-665.		69
250	Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver. , 1999, 81, 767-771.		36
251	Pre-clinical evaluation of [111In-DTPA-Pro1, Tyr4]bombesin, a new radioligand for bombesin-receptor scintigraphy. , 1999, 83, 657-663.		69
252	Identification of Thyroid Hormone Transporters. Biochemical and Biophysical Research Communications, 1999, 254, 497-501.	1.0	166

#	Article	IF	Citations
253	Internalization of [DOTAo,125I-Tyr3]Octreotide by Somatostatin Receptor-Positive Cells In Vitro and In Vivo: Implications for Somatostatin Receptor-Targeted Radio-guided Surgery. Proceedings of the Association of American Physicians, 1999, 111, 63-69.	2.1	44
254	Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. , 1998, 75, 406-411.		109
255	Somatostatin receptor scintigraphy using [111 In-DTPA 0]RC-160 in humans: a comparison with [111 In-DTPA 0]octreotide. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 182-186.	3.3	18
256	Somatostatin receptor imaging in patients with sarcoidosis. European Journal of Nuclear Medicine and Molecular Imaging, 1998, 25, 1284-1292.	3.3	79
257	99mTc-MIBI, 99mTc-Tetrofosmin and 99mTc-Q12 In Vitro and In Vivo. Nuclear Medicine and Biology, 1998, 25, 233-240.	0.3	42
258	Bone Mineral Density and Body Composition before and during Treatment with Gonadotropin-Releasing Hormone Agonist in Children with Central Precocious and Early Puberty1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 370-373.	1.8	73
259	Ontogeny of Iodothyronine Deiodinases in Human Liver1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 2868-2874.	1.8	115
260	Rapid Sulfation of 3,3â€²,5â€²-Triiodothyronine in NativeXenopus laevisOocytes. Endocrinology, 1998, 139, 596-600.	1.4	13
261	Expression of Rat Liver Cell Membrane Transporters for Thyroid Hormone inXenopus laevisOocytes1. Endocrinology, 1997, 138, 1841-1846.	1.4	34
262	Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency¹. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2423-2428.	1.8	180
263	Bone Mineral Density in Children and Adolescents: Relation to Puberty, Calcium Intake, and Physical Activity1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 57-62.	1.8	391
264	Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 368-371.	2.2	159
265	Effects of ligand priming and multiple-dose injection on tissue uptake of 111In-pentetreotide in rats. Nuclear Medicine and Biology, 1997, 24, 749-753.	0.3	5
266	Comparison of dobutamine stress echocardiography and technetium-99m sestamibi single-photon emission tomography for the diagnosis of coronary artery disease in hypertensive patients with and without left ventricular hypertrophy. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 25, 69-78.	3.3	42
267	Site-specific intravascular administration of drugs: History of a method applicable in humans. , 1997, 41, 342-347.		3
268	Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA 0 , d -Phe 1 ,Tyr 3]octreotide, a promising somatostatin analogue for radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 368-371.	3.3	62
269	Site-Specific Intracoronary Heparin Delivery in Humans After Balloon Angioplasty. Circulation, 1997, 96, 154-165.	1.6	73
270	Prognostic value of dobutamine-atropine stress technetium-99m sestamibi perfusion scintigraphy in patients with chest pain. Journal of the American College of Cardiology, 1996, 28, 447-454.	1.2	48

#	Article	IF	Citations
271	Low-dose dobutamine echocardiography and rest-redistribution thallium-201 tomography in the assessment of spontaneous recovery of left ventricular function after recent myocardial infarction. American Heart Journal, 1996, 131, 1088-1096.	1.2	35
272	Comparison of uptake of99mTc-MIBI,99mTc-tetrofosmin and99mTc-012 into human breast cancer cell lines. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1361-1366.	2.2	39
273	Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 775-781.	2.2	22
274	Different Regulation of Thyroid Hormone Transport in Liver and Pituitary: Its Possible Role in the Maintenance of Low T3 Production during Nonthyroidal Illness and Fasting in Man. Thyroid, 1996, 6, 359-368.	2.4	41
275	Somatostatin Receptors in Gastroenteropancreatic Tumors. Digestive Surgery, 1996, 13, 161-169.	0.6	3
276	Somatostatin Receptor Scintigraphy in Patients with Carcinoid Tumors. World Journal of Surgery, 1996, 20, 157-161.	0.8	54
277	The Use of Somatostatin Receptor Scintigraphy in the Differential Diagnosis of Pancreatic Duct Cancers and Islet Cell Tumors. Annals of Surgery, 1996, 224, 119-124.	2.1	48
278	Echocardiographic and Radionuclide Pulmonary Blood Flow Patterns After Transcatheter Closure of Patent Ductus Arteriosus. Circulation, 1996, 94, 126-129.	1.6	37
279	Evaluation in vitro and in rats of161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 608-616.	2.2	65
280	Minireview: Receptor Imaging of Human Diseases Using Radiolabeled Peptides. Journal of Receptor and Signal Transduction Research, 1995, 15, 379-392.	1.3	11
281	Transport of thyroxine into cultured hepatocytes: effects of mild nonâ€thyroidal illness and calorie restriction in obese subjects. Clinical Endocrinology, 1994, 40, 79-85.	1.2	33
282	Somatostatin receptor scintigraphy: Its value in tumor localization in patients with cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. American Journal of Medicine, 1994, 96, 305-312.	0.6	110
283	Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis. European Journal of Pharmacology, 1994, 271, 371-378.	1.7	52
284	Adaptive changes in transmembrane transport and metabolism of triiodothyronine in perfused livers of fed and fasted hypothyroid and hyperthyroid rats. Metabolism: Clinical and Experimental, 1994, 43, 1355-1361.	1.5	8
285	The Role of Somatostatin Receptor Scintigraphy in Gastroenteropancreatic Endocrine Tumors. Digestive Surgery, 1994, 11, 456-460.	0.6	1
286	Somatostatin analogue scintigraphy in carcinoid tumours. European Journal of Nuclear Medicine and Molecular Imaging, 1993, 20, 283-92.	2.2	148
287	Octreotide and Related Somatostatin Analogs in the Diagnosis and Treatment of Pituitary Disease and Somatostatin Receptor Scintigraphy. Frontiers in Neuroendocrinology, 1993, 14, 27-55.	2.5	47
288	Reduced T3 deiodination by the human hepatoblastoma cell line HepG2 caused by deficient T3 sulfation. Biochimica Et Biophysica Acta - General Subjects, 1993, 1157, 114-118.	1.1	7

#	Article	IF	Citations
289	Validation of Somatostatin Receptor Scintigraphy in the Localization of Neuroendocrine Tumors. Acta OncolÃ³gica, 1993, 32, 167-170.	0.8	33
290	Somatostatin Analogs in the Treatment of Acromegaly. Endocrinology and Metabolism Clinics of North America, 1992, 21, 737-752.	1.2	37
291	Endocrine aspects of the diagnosis and treatment of primary brain tumours. Clinical Endocrinology, 1992, 37, 1-10.	1.2	14
292	Graft regeneration and host liver atrophy after auxiliary heterotopic liver transplantation for chronic liver failure. Hepatology, 1992, 15, 54-57.	3.6	17
293	Thyroxine and 3,3â€²,5-Triiodothyronine Are Glucuronidated in Rat Liver by Different Uridine Diphosphate-Glucuronyltransferases*. Endocrinology, 1991, 128, 741-746.	1.4	117
294	The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors. Endocrine Reviews, 1991, 12, 450-482.	8.9	776
295	Euro-Collins Solution Versus Uw-Solution for Long-Term Liver Preservation in the Isolated Rat-Liver Perfusion Model. HPB Surgery, 1991, 4, 313-320.	2.2	5
296	Parallelin Vivoandin VitroDetection of Functional Somatostatin Receptors in Human Endocrine Pancreatic Tumors: Consequences with Regard to Diagnosis, Localization, and Therapy. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 566-574.	1.8	190
297	Clinical applications of somatostatin analogs. Trends in Endocrinology and Metabolism, 1990, 1, 139-144.	3.1	18
298	2 The clinical use of somatostatin analogues in the treatment of cancer. Bailliere's Clinical Endocrinology and Metabolism, 1990, 4, 29-49.	1.0	30
299	Combined measurements of plasma aromatic l-amino acid decarboxylase and DOPA as tumour markers in diagnosis and follow-up of neuroblastoma. European Journal of Cancer & Clinical Oncology, 1989, 25, 1045-1052.	0.9	12
300	Prednisone and Cyclosporine in the Treatment of Severe Graves' Ophthalmopathy. New England Journal of Medicine, 1989, 321, 1353-1359.	13.9	321
301	Deiodination of Thyroid Hormone by Human Liver. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 17-24.	1.8	112
302	CARRIER-MEDIATED TRANSPORT OF THYROID HORMONE INTO RAT HEPATOCYTES IS RATE-LIMITING IN TOTAL CELLULAR UPTAKE AND METABOLISM. Endocrinology, 1986, 119, 1870-1872.	1.4	63
303	Carrier-Mediated Transport of Thyroid Hormone (TH) into Rat Hepatocytes is Rate Limiting in Total Cellular Uptake and Metabolism. , 1986, , 553-556.		0
304	Evidence that the uptake of tri-iodo-l-thyronine by human erythrocytes is carrier-mediated but not energy-dependent. Biochemical Journal, 1982, 208, 27-34.	1.7	32
305	Decreased transport of thyroxine (T4), 3,3â€²-5-triiodothyronine (T3) and 3,3â€²,5â€²-triiodothyronine (rT3) into rat hepatocytes in primary culture due to a decrease of cellular ATP content and various drugs. FEBS Letters, 1982, 140, 229-233.	1.3	90
306	Neuroendocrine Tumors. , 0, , 564-668.		0

#	Article	IF	Citations
307	Expression of Rat Liver Cell Membrane Transporters for Thyroid Hormone in Xenopus laevis Oocytes. , 0, .		14
308	Thyroid Hormone Transport by the Heterodimeric Human System L Amino Acid Transporter. , 0, .		48
309	Longitudinal Follow-Up of Bone Density and Body Composition in Children with Precocious or Early Puberty before, during and after Cessation of GnRH Agonist Therapy. , 0, .		24